Krystal Biotech (KRYS) News Today

Krystal Biotech, Inc. (NASDAQ: KRYS) shares traded mixed following a series of corporate updates, analyst revisions and insider transactions. Below is a breakdown of the key drivers likely influencing today’s move:

• Positive Sentiment: Citi raised its price target for KRYS to $176, citing encouraging progress in the Phase I/II KB801 gene-therapy eye-drop trial. Citi Raises Price Target
• Positive Sentiment: KRYS began dosing patients in its KB801 program targeting neurotrophic keratitis, lifting sentiment around its rare eye-disease pipeline. KB801 Trial Dosing Begins
• Neutral Sentiment: Short interest remained flat at zero shares as of July 10th, with a days-to-cover ratio of 0.0, indicating minimal short-seller pressure.
• Negative Sentiment: Insider Suma Krishnan sold approximately 13,927 shares at an average price near $150, reducing her stake by nearly 1%. Insider Selling Notice
• Negative Sentiment: William Blair cut its Q2 2025 EPS estimate for KRYS to $1.36 from $1.47, reflecting more conservative near-term earnings forecasts. EPS Estimate Cut